Skip to main content

Table 1 Disease characteristics and biomarker levels at baseline*

From: The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

  Placebo→Infliximab 6 mg/kg + MTX Infliximab 3 mg/kg + MTX
Patients included in substudy 38 34
Age at study entry, yrs 12.7 (3.3) 13.4 (2.8)
Disease characteristics   
Disease duration, yrs 4.03 (3.92) 4.89 (4.4)
   Number of joints with active arthritis   
n 38 34
Range (5.0, 47.9) (5.0, 44.0)
Median 16.0 13.5
   Number of joints with limited range of motion   
n 38 34
Range (4.0, 48.4) (2.0, 42.0)
Median 15.0 12.5
Inflammatory markers   
   C-reactive protein, mg/dL   
n 38 34
Range (0.4, 7.4) (0.4, 10.5)
Median 0.8 0.9
   TNF-α (pg/mL)   
n 14 9
Range (1.6, 30.9) (1.6, 24.4)
Median 1.6 1.6
   IL-6 (pg/mL)   
n 28 27
Range (0.4, 93.7) (0.1, 79.3)
Median 8.2 3.4
   MMP-3 (ng/mL)   
n 32 32
Range (2.7, 390.2) (0.8, 570.0)
Median 39.3 40.3
   ICAM-1 (ng/mL)   
n 34 32
Range (200.2, 767.9) (18.6, 1059.2)
Median 394.0 375.4
   VEGF (ng/mL)   
n 33 32
Range (83.3, 1535.2) (29.8, 1447.0)
Median 440.2 317.8
   IL-12p40 (pg/mL)   
n 34 30
Range (15.5, 357.9) (15.6, 357.9)
Median 84.3 95.6
  1. Values are presented as mean (SD) unless otherwise noted.
  2. * Only patients with biomarker values above the lower limit of quantification of specific assays were included in analyses, which accounts for differences between numbers of patients sampled for each inflammatory marker.
  3. MTX, methotrexate; IL-6, interleukin-6; MMP-3, matrix metalloproteinase-3; ICAM-1, intracellular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; IL-12p40, interleukin 12; TNF-α, tumor necrosis factor-α.